In the pharmaceutical industry, compliance with the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) regulations is crucial. These regulations, overseen by the European Chemical Agency (ECHA), are instrumental in ensuring the safety and environmental impact of industrial chemicals used in pharmaceutical processes. Adgyl Life Sciences helps actively support and facilitate adherence to REACH requirements, enhancing the pharmaceutical sector’s commitment to safety and compliance.
As a trusted partner in the pharmaceutical industry, Adgyl Life Sciences takes the lead in providing comprehensive REACH Studies, aligning with the regulatory requirements set forth by the European Chemical Agency (ECHA).
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Studies) is a regulatory requirement of European Chemical Agency (ECHA). It requires that all companies manufacturing or importing chemical substances into the European Union in quantities of one ton or more per year to register these substances with ECHA. REACH addresses the production and use of chemical substances, and their potential impacts on both human health and the environment.
Adgyl Lifesciences has experience and expertise in designing the REACH studies as per European Chemical Agency (ECHA) requirements. Adgyl has completed more than 100 REACH packages and submitted to Agency in the International Uniform Chemical Information Database (IUCLID) format.